Announcement • Jul 16
ARYA Sciences Acquisition Corp IV, Annual General Meeting, Jul 26, 2024 ARYA Sciences Acquisition Corp IV, Annual General Meeting, Jul 26, 2024. Location: at the offices of kirkland & ellis llp, located at 601 lexington avenue, new york,10022, new york United States Announcement • May 18
ARYA Sciences Acquisition Corp IV announced delayed 10-Q filing On 05/16/2024, ARYA Sciences Acquisition Corp IV announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Mar 31
ARYA Sciences Acquisition Corp IV Faces Additional Delisting Notice from Nasdaq Amid Listing Rule Deficiency As previously disclosed, ARYA Sciences Acquisition Corp. IV received a notice from the staff of the Listing Qualifications Department (the ‘Listing Department’) of The Nasdaq Stock Market LLC (‘Nasdaq’) on January 29, 2024, stating that the company failed to hold an annual meeting of shareholders within twelve months of the end of its fiscal year ended December 31, 2022, as required by Nasdaq Listing Rule 5620(a). Additionally, as previously disclosed, the company received a notice from the staff of the Listing Department of Nasdaq indicating that, unless the company timely requests a hearing before the Nasdaq Hearings Panel (the ‘Panel’), trading of the company’s securities on the Nasdaq Capital Market would be suspended due to the company’s non-compliance with Nasdaq IM-5101-2, which requires that a special purpose acquisition company complete one or more business combinations within 36 months of the effectiveness of its initial public offering registration statement. the company timely requested a hearing before the Panel to request sufficient time to complete the company’s previously disclosed proposed business combination (the ‘Business Combination’) with Adagio Medical Inc. (‘Adagio’). Such hearing request resulted in a stay of the suspension or delisting action. Subsequently, on March 26, 2024, the company received an additional and separate notice from the staff of the Listing Department of Nasdaq formally notifying the company that the deficiency under Nasdaq Listing Rule 5620(a) serves as an additional and separate basis for delisting and that the Panel will consider such additional matter at the company’s upcoming hearing (currently scheduled on April 25, 2024) to render a determination on the company’s continued listing on The Nasdaq Capital Market. There can be no assurance that the company will be able to satisfy Nasdaq’s continued listing requirements, obtain a favorable determination of the Panel on the company’s ability to remain listed on the Nasdaq Capital Market and maintain compliance with other Nasdaq listing requirements. 
